open access

Vol 78, No 1 (2010)
ORIGINAL PAPERS
Published online: 2010-01-29
Submitted: 2013-02-22
Get Citation

Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival

Monika Załęska, Monika Szturmowicz, Jacek Zych, Barbara Roszkowska-Śliż, Urszula Demkow, Renata Langfort, Kazimierz Roszkowski-Śliż
Pneumonol Alergol Pol 2010;78(1):14-20.

open access

Vol 78, No 1 (2010)
ORIGINAL PAPERS
Published online: 2010-01-29
Submitted: 2013-02-22

Abstract

The aim of the study was to evaluate the predictive and prognostic values of elevated serum levels of selected cancer markers (NSE, Cyfra 21-1, CEA, ferritin, free beta-hCG, LDH) in patients with inoperable non-small-cell lung cancer (NSCLC). We investigated a group of 79 patients (49 men and 30 women) with NSCLC. Multivariate regression analysis showed response in patients with NSE > 12.5 ng/ml (p = 0.002), good performance status (p = 0.007) and elderly patients (p = 0.005). However, elevated NSE adversely affected the prognosis. Median survival in patients with NSE < 12.5 ng/ml, 12.5-20.0 ng/ml and > 20.0 ng/ml was 13.3, 11.3 and 6.7 months, respectively (p = 0.004). The negative effect of elevated NSE was independent of the response category. Univariate regression analysis showed that the following factors had a significantly negative effect on the prognosis: performance status, stage IIIB or IV, weight loss of > 10%, NSE > 20 ng/ml, Cyfra 21-1 > 10 ng/ml, CEA > 3 ng/ml, ferritin ratio > 1 and LDH > 480 IU/l. Multivariate analysis showed an independent adverse prognostic effect of stage IIIB or IV and elevated ferritin.

Abstract

The aim of the study was to evaluate the predictive and prognostic values of elevated serum levels of selected cancer markers (NSE, Cyfra 21-1, CEA, ferritin, free beta-hCG, LDH) in patients with inoperable non-small-cell lung cancer (NSCLC). We investigated a group of 79 patients (49 men and 30 women) with NSCLC. Multivariate regression analysis showed response in patients with NSE > 12.5 ng/ml (p = 0.002), good performance status (p = 0.007) and elderly patients (p = 0.005). However, elevated NSE adversely affected the prognosis. Median survival in patients with NSE < 12.5 ng/ml, 12.5-20.0 ng/ml and > 20.0 ng/ml was 13.3, 11.3 and 6.7 months, respectively (p = 0.004). The negative effect of elevated NSE was independent of the response category. Univariate regression analysis showed that the following factors had a significantly negative effect on the prognosis: performance status, stage IIIB or IV, weight loss of > 10%, NSE > 20 ng/ml, Cyfra 21-1 > 10 ng/ml, CEA > 3 ng/ml, ferritin ratio > 1 and LDH > 480 IU/l. Multivariate analysis showed an independent adverse prognostic effect of stage IIIB or IV and elevated ferritin.
Get Citation

Keywords

neuron specific enolase; non-small-cell lung cancer; prognosis; response to treatment

About this article
Title

Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival

Journal

Advances in Respiratory Medicine

Issue

Vol 78, No 1 (2010)

Pages

14-20

Published online

2010-01-29

Bibliographic record

Pneumonol Alergol Pol 2010;78(1):14-20.

Keywords

neuron specific enolase
non-small-cell lung cancer
prognosis
response to treatment

Authors

Monika Załęska
Monika Szturmowicz
Jacek Zych
Barbara Roszkowska-Śliż
Urszula Demkow
Renata Langfort
Kazimierz Roszkowski-Śliż

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl